People
Achilles Therapeutics, a biopharmaceutical company developing personalised cancer immunotherapies, announces it has appointed Beverley Carr as Chief Business Officer, with effect from 4 November 2019.
When it comes to specific attributes, having the opportunity to do interesting and meaningful work, securing a competitive salary and having access to quality health benefits were the most important. Here are some differences when it comes to generational priorities.
Plexium is focused on developing therapeutics that influence E3 ligases that can degrade proteins, even the undruggable ones. The company’s founder and chief executive officer Kandaswamy “Swamy” Vijayan, took time out to speak with BioSpace about the company and its technology platform, DELPHe.
According to the report, the majority of the cuts will occur in the company’s Human Health Division and are expected to begin Jan. 3 and conclude Jan. 16, 2020.
HepaRegeniX GmbH, a preclinical stage company developing a novel therapy for the treatment of acute and chronic liver diseases announced the appointment of seasoned biotech expert Dr. Michael Lutz as new CEO and Managing Director of the company..
Pharma, biotech and medtech companies strengthen their executive ranks and boards with this week’s Movers & Shakers.
Reenie McCarthy, chief executive officer of Stealth Biotherapeutics, has seen first-hand the negative impact of mitochondrial diseases, including watching an athlete decline from being an Olympic-level rower to becoming wheelchair-bound.
Netherlands-based Pharming Group NV has denied any involvement in a potential theft of intellectual property belonging to CSL Behring from Joseph Chiao, who recently joined Pharming as medical director.
Life Science Integrates welcomes you to this year’s Pharma Integrates conference in London on 18th and 19th November
Frank Reynolds, chief executive officer of PixarBio, made outlandish claims to investors and even compared himself to Apple’s Steve Jobs and Jesus Christ. Those were the claims of a witness made on the witness stand in an ongoing securities fraud trial.
PRESS RELEASES